(Q35183026)

7 August 2017

1 reference

title

Botulinum toxin as a new therapy option for voiding disorders: current state of the art. (English)

1 reference

7 August 2017

Thomas Leippold

1

1 reference

7 August 2017

André Reitz

series ordinal

2

1 reference

7 August 2017

Brigitte Schurch

series ordinal

3

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

44

1 reference

7 August 2017

2

1 reference

7 August 2017

165-174

1 reference

Molecular pharmacology of botulinum toxin and tetanus toxin

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Human response to botulinum toxin injection: type B compared with type A

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Pharmacology and immunology of botulinum toxin serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Axotomy-like changes in cat motoneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum toxin: the story of its development for the treatment of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum A toxin in spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum toxin in the treatment of chronic urinary retention in women

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

The male chronic pelvic pain syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Oxybutynin in bladder spasm, neurogenic bladder, and enuresis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Maximal electrical stimulation for urinary incontinence: report of 98 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

The first 500 patients with sacral anterior root stimulator implants: general description

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Intravesical capsaicin for treatment of detrusor hyperreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Suppression of bladder hyperreflexia by intravesical resiniferatoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Treatment of neurogenic incontinence with botulinum toxin A

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

BOTULISM. STUDIES ON THE MANNER IN WHICH THE TOXIN OF CLOSTRIDIUM BOTULINUM ACTS UPON THE BODY : I. THE EFFECT UPON THE AUTONOMIC NERVOUS SYSTEM.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Botulinum toxin for palmar hyperhidrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Treatment of gustatory sweating with botulinum toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Motor responses of the urinary bladder and skeletal muscle inBotulinumintoxicated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900250-1

7 January 2021

10.1016/S0302-2838(03)00250-1

Identifiers

DOI

1 reference

7 August 2017

1 reference